Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.17 USD | -8.59% | -4.10% | +35.26% |
Financials (USD)
Sales 2024 * | 147M | Sales 2025 * | 165M | Capitalization | 136M |
---|---|---|---|---|---|
Net income 2024 * | -146M | Net income 2025 * | -182M | EV / Sales 2024 * | 1.44 x |
Net Debt 2024 * | 74M | Net cash position 2025 * | - | EV / Sales 2025 * | 0.83 x |
P/E ratio 2024 * |
-0.96
x | P/E ratio 2025 * |
-1.11
x | Employees | 325 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.01% |
Latest transcript on Karyopharm Therapeutics Inc.
1 day | -8.59% | ||
1 week | -4.10% | ||
Current month | -22.52% | ||
1 month | -14.60% | ||
3 months | +52.74% | ||
6 months | +10.38% | ||
Current year | +35.26% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Paulson
CEO | Chief Executive Officer | 56 | 20-02-25 |
Mike Mason
DFI | Director of Finance/CFO | 49 | 19-02-24 |
Amama Sadiq
CTO | Chief Tech/Sci/R&D Officer | - | 23-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Garen Bohlin
BRD | Director/Board Member | 76 | 13-10-02 |
Barry Greene
BRD | Director/Board Member | 60 | 12-12-31 |
Director/Board Member | 59 | 13-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 1.17 | -8.59% | 1,441,884 |
24-04-18 | 1.28 | -7.25% | 1,306,165 |
24-04-17 | 1.38 | +25.45% | 3,175,612 |
24-04-16 | 1.1 | -4.76% | 1,171,346 |
24-04-15 | 1.155 | -5.33% | 810,682 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.26% | 136M | |
-3.10% | 102B | |
+2.11% | 96.37B | |
-1.80% | 21.37B | |
-17.75% | 20.92B | |
-6.91% | 18.64B | |
-42.00% | 16.4B | |
-28.19% | 13.53B | |
+0.18% | 13.28B | |
+19.90% | 10.85B |
- Stock Market
- Equities
- KPTI Stock